Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 15/20 | 0.39 |
| ▸ | AKT3 | Q9Y243 | 11/20 | 0.39 |
| ▸ | AKT2 | P31751 | 10/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17634051 | 1.00 | AKT1 (0.39) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL192015 | 0.84 | KIT (0.48) | ALDH1A1 | |
| SCHEMBL192014 | 0.84 | KIT (0.48) | ALDH1A1 | |
| SCHEMBL12194049 | 0.84 | HRH4 (0.41) | CYP1A2CYP3A4ACHEBACE1MEN1 | |
| SCHEMBL16488552 | 0.82 | JAK2 (0.39) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL19283120 | 0.82 | AKT1 (0.34) | AKT1AKT3AKT2MEN1KMT2A | |
| SCHEMBL16624829 | 0.81 | AKT3 (0.33) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL3939523 | 0.81 | AKT1 (0.32) | AKT1AKT3AKT2CYP1A2CYP3A4 | |
| SCHEMBL17629229 | 0.80 | HTR2C (0.40) | CYP1A2CYP3A4MEN1KMT2AKDM4E | |
| SCHEMBL3663646 | 0.80 | MAPT (0.43) | AKT1AKT3AKT2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109540-A1 | HETEROCYCLIC COMPOUND WITH AKT KINASE INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2023-06-22 | — | — | WO | disclosed |
| EP-3626710-B1 | PROCESS FOR PREPARING AN INTERMEDIATE IN THE SYNTHESIS OF (CYCLOPENTYL[D]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-10870626-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2020-12-22 | — | — | US | disclosed |
| CN-112062727-A | Process for preparing (cyclopenta [ d ] pyrimidin-4-yl) piperazine compounds | 豪夫迈·罗氏有限公司 | 2020-12-11 | — | — | CN | disclosed |
| CN-107001287-B | Process for preparing (cyclopenta [ d ] pyrimidin-4-yl) piperazine compounds | 豪夫迈·罗氏有限公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-3626710-A1 | PROCESSES FOR PREPARING (CYCLOPENTYL[D]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2020-03-25 | — | — | EP | disclosed |
| US-10457648-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | GENENTECH INC. (US) | 2019-10-29 | — | — | US | disclosed |
| EP-3197875-B1 | PROCESSES FOR PREPARING (CYCLOPENTYL[D]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2019-08-14 | — | — | EP | disclosed |
| US-20170247338-A1 | PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. HOFFMAN-LA ROCHE AG (CH) | 2017-08-31 | — | — | US | disclosed |
| EP-3197875-A1 | PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9409886-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-06-02 | — | — | US | disclosed |
| WO-2016049414-A1 | PROCESSES FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-03-31 | — | — | WO | disclosed |
| EP-2170863-B1 | Pyrimido cyclopentanes useful for the treatment of inflammatory or hyperproliferative diseases | ARRAY BIOPHARMA INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | GENETECH, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8618097-B2 | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2013-12-31 | — | — | US | disclosed |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2170863-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009006567-A2 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099881-A1 | PROCESS FOR MAKING HYDROXYLATED CYCLOPENTYLPYRIMIDINE COMPOUNDS | PIK3CA, DHPS, PIK3CD | AKT1 24/4885AKT3 30/4885AKT2 19/4885 |
| US-10870626-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | PAK5, CDK5, PPIP5K2 | AKT1 114/4885AKT3 193/4885AKT2 96/4885 |
| US-20140080829-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT1 3/4885AKT3 8/4885AKT2 4/4885 |
| US-20170247338-A1 | PROCESS FOR PREPARING (CYCLOPENTYL[d]PYRIMIDIN-4-YL)PIPERAZINE COMPOUNDS | PAK5, CDK5, PPIP5K2 | AKT1 114/4885AKT3 193/4885AKT2 96/4885 |
| US-20160152601-A9 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT1 3/4885AKT3 8/4885AKT2 4/4885 |
| US-10457648-B2 | Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds | PAK5, CDK5, PPIP5K2 | AKT1 114/4885AKT3 193/4885AKT2 96/4885 |
| US-20110015204-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | TK1, PIK3CA, AKT1 | AKT1 3/4885AKT3 8/4885AKT2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.